ClinPhone has appointed Graeme Hart and Keith Bragman as non-executive directors, following the company's successful IPO launch on the London Stock Exchange in June 2006
ClinPhone currently employs more than 600 staff worldwide, providing services to 100,000 clinical trials sites.
The latest appointments will further strengthen the board of directors as the business moves into its next stage of development.
Graeme Hart is an orthopaedic surgeon and his extensive public company experience includes NW Herts NHS Trust, Huntleigh Technology, and Evolutec where he is also a non-executive director.
Hart is also chairman of Thornbury Nursing Services and non-executive chairman of Corin, and was formerly chairman of Healthcare Services and Crestacare.
With broad strategic and senior management experience at all stages of clinical drug development, across a diverse range of therapeutic areas, Keith Bragman is currently an advisor to industry and government sponsored institutions.
Bragman is an independent director of BruCells, a biotechnology company developing cellular vaccines for the treatment of cancer, and has previously held appointments in senior clinical management at UCB, Quintiles, Hoffmann-la Roche and Bristol Myers International.
Bragman is a member of the Ethical Issues Committee, Faculty of Pharmaceutical Medicine, Royal Colleges of Physicians of the United Kingdom and the Scientific Advisory Board, Unibioscreen.
"Our company continues to grow, strengthening its board and senior management positions following the successful float in June 2006.
"Both Dr Hart and Dr Bragman bring experience and skills which will positively contribute to future of ClinPhone in the marketplace," comments Steve Kent, CEO of ClinPhone.
